Astrazeneca (AZN) Accumulated Expenses (2015 - 2025)

Astrazeneca's Accumulated Expenses history runs 11 years deep, the most recent figure standing at $7.3 billion for Q4 2025.

• In Q4 2025, Accumulated Expenses rose 12.3% year-over-year to $7.3 billion; the TTM figure through Dec 2025 stood at $7.3 billion (up 12.3% YoY), while the FY2025 annual figure was $7.3 billion, up 12.3% from the prior year.
• Accumulated Expenses was $7.3 billion for Q4 2025 at Astrazeneca, up from $6.5 billion in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $7.3 billion in Q4 2025 to a low of -$911.0 million in Q1 2021.
• Historically, Accumulated Expenses has averaged $5.0 billion across 5 years, with a median of $5.9 billion in 2021.
• The sharpest annual moves came in 2021 and 2022: Accumulated Expenses soared 44.66% in 2021, then fell 1.73% in 2022.
• A 5-year view of Accumulated Expenses shows it stood at $5.6 billion in 2021, then retreated by 1.73% to $5.6 billion in 2022, then climbed by 10.11% to $6.1 billion in 2023, then advanced by 5.74% to $6.5 billion in 2024, then increased by 12.3% to $7.3 billion in 2025.
• The last three Accumulated Expenses figures came in at $7.3 billion (Q4 2025), $6.5 billion (Q4 2024), and $6.1 billion (Q4 2023), per Business Quant data.